welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy
study id #: NCT01099761
condition: Duchenne Muscular Dystrophy
status: terminated
purpose:The purpose of this study is to determine if ACE-031 is safe and well-tolerated in boys with Duchenne Muscular Dystrophy (DMD) and to select the optimal doses of ACE-031 in terms of safety and pharmacodynamic (PD) activity for designing future studies. [Note: This study was terminated based on safety data]
intervention: ACE-031 0.5 mg/kg q4wk, ACE-031 1.0 mg/kg q2wk, Placebo
mechanism of action: Myostatin inhibitor to promote muscle growth
results: https://clinicaltrials.gov/ct2/show/results/NCT01099761
last updated: November 22, 2018
rareRelated
-
A Randomized, Double-blind, Placebo-controlled Study of SRP-9001 for Duchenne Muscular Dystrophy (DMD)The purpose of this study is to evaluate...
-
Study of Eteplirsen in Young Patients With DMD Amenable to Exon 51 SkippingThis is a multicenter, open-label, dose-...
-
A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD)The purpose of this study is to determin...
-
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular DystrophyThe main purpose of this study is to tes...
-
Safety Study of BLS-M22 in Healthy VolunteersBLS-M22 is being developed as an anti-my...
-
HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)Male subjects with cardiomyopathy second...
-
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)The purpose of this study is to determin...
-
BIOPHYTIS to Host Key Opinion Leader Meeting on the Biology of Aging and its Application in Neuromuscular DiseasesBiophytis, a clinical-stage biotechnolog...
-
A phase 2 trial of the safety and pharmacokinetics of ataluren in patients aged 2 to 5 years with nonsense mutation ...Nonsense mutation Duchenne muscular dyst...
-
First Patient Dosed in Phase II Clinical Trial in Duchenne Muscular DystrophyAntisense Therapeutics today announced d...
-
PTC Therapeutics Announces Positive Data from its Translarna™ Phase II Clinical Trial in Children as Young as Two ...PTC Therapeutics, Inc. today announced t...
-
Wave Life Sciences Duchenne Muscular Dystrophy Clinical Trial Selected for FDA Complex Innovative Trial Designs Pilo...Wave Life Sciences Ltd., a biotechnology...